Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
459.81
-3.46 (-0.75%)
At close: Jul 18, 2025, 4:00 PM
458.13
-1.68 (-0.37%)
After-hours: Jul 18, 2025, 7:22 PM EDT
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
The 25 analysts that cover Vertex Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $509, which forecasts a 10.7% increase in the stock price over the next year. The lowest target is $420 and the highest is $583.
Price Target: $509 (+10.7%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 10 | 9 | 8 |
| Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Hold | 10 | 10 | 10 | 11 | 11 | 11 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 25 | 25 | 26 | 27 | 26 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $515 → $517 | Buy | Maintains | $515 → $517 | +12.44% | Jul 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $550 | Strong Buy | Reiterates | $550 | +19.61% | Jun 23, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $464 → $460 | Hold | Maintains | $464 → $460 | +0.04% | Jun 20, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $423 → $420 | Hold | Maintains | $423 → $420 | -8.66% | Jun 17, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $420 → $423 | Hold | Maintains | $420 → $423 | -8.01% | May 6, 2025 |
Financial Forecast
Revenue This Year
12.17B
from 11.02B
Increased by 10.43%
Revenue Next Year
13.49B
from 12.17B
Increased by 10.81%
EPS This Year
18.30
from -2.08
EPS Next Year
21.10
from 18.30
Increased by 15.30%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 12.9B | 15.7B | 17.7B | |
| Avg | 12.2B | 13.5B | 14.7B | |
| Low | 11.5B | 11.7B | 11.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 16.7% | 29.0% | 31.3% | |
| Avg | 10.4% | 10.8% | 9.1% | |
| Low | 4.5% | -3.9% | -14.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 19.73 | 28.05 | 33.75 | |
| Avg | 18.30 | 21.10 | 23.41 | |
| Low | 16.56 | 17.36 | 18.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | - | 53.2% | 59.9% | |
| Avg | - | 15.3% | 10.9% | |
| Low | - | -5.2% | -11.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.